Nature Communications (Jun 2020)
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
- Tarek H. Mouhieddine,
- Adam S. Sperling,
- Robert Redd,
- Jihye Park,
- Matthew Leventhal,
- Christopher J. Gibson,
- Salomon Manier,
- Amin H. Nassar,
- Marzia Capelletti,
- Daisy Huynh,
- Mark Bustoros,
- Romanos Sklavenitis-Pistofidis,
- Sabrin Tahri,
- Kalvis Hornburg,
- Henry Dumke,
- Muhieddine M. Itani,
- Cody J. Boehner,
- Chia-Jen Liu,
- Saud H. AlDubayan,
- Brendan Reardon,
- Eliezer M. Van Allen,
- Jonathan J. Keats,
- Chip Stewart,
- Shaadi Mehr,
- Daniel Auclair,
- Robert L. Schlossman,
- Nikhil C. Munshi,
- Kenneth C. Anderson,
- David P. Steensma,
- Jacob P. Laubach,
- Paul G. Richardson,
- Jerome Ritz,
- Benjamin L. Ebert,
- Robert J. Soiffer,
- Lorenzo Trippa,
- Gad Getz,
- Donna S. Neuberg,
- Irene M. Ghobrial
Affiliations
- Tarek H. Mouhieddine
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Adam S. Sperling
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Robert Redd
- Department of Data Sciences, Dana-Farber Cancer Institute
- Jihye Park
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Matthew Leventhal
- Broad Institute of MIT and Harvard
- Christopher J. Gibson
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Salomon Manier
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Amin H. Nassar
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Marzia Capelletti
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Daisy Huynh
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Mark Bustoros
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Romanos Sklavenitis-Pistofidis
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sabrin Tahri
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Kalvis Hornburg
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Henry Dumke
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Muhieddine M. Itani
- Massachusetts General Hospital
- Cody J. Boehner
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Chia-Jen Liu
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Saud H. AlDubayan
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Brendan Reardon
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Eliezer M. Van Allen
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jonathan J. Keats
- Integrated Cancer Genomics Division, Translational Genomics Research Institute
- Chip Stewart
- Department of Data Sciences, Dana-Farber Cancer Institute
- Shaadi Mehr
- Multiple Myeloma Research Foundation
- Daniel Auclair
- Multiple Myeloma Research Foundation
- Robert L. Schlossman
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Nikhil C. Munshi
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Kenneth C. Anderson
- Department of Medical Oncology, Dana-Farber Cancer Institute
- David P. Steensma
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jacob P. Laubach
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Paul G. Richardson
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jerome Ritz
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Benjamin L. Ebert
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Robert J. Soiffer
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Lorenzo Trippa
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Gad Getz
- Broad Institute of MIT and Harvard
- Donna S. Neuberg
- Department of Data Sciences, Dana-Farber Cancer Institute
- Irene M. Ghobrial
- Department of Medical Oncology, Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-020-16805-5
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 9
Abstract
Multiple myeloma (MM) is treated with induction chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. Here, the authors show that the presence of clonal haematopoiesis of indeterminate potential (CHIP) at time of ASCT is associated with adverse outcomes in MM patients.
